Clinical trials: Artery; Thrombosis
Peripheral Arterial Disease, Venous Thormboembolism
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures.
- Conditions
- Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases, Vascular Surgery Patient with PAD / Carotid Stenosis
- Trial name
- RESOLUTION (NCT06873321)
- Testing
- rivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Science Valley Research Institute
Coronary Artery Disease
Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study
Vascular effects evaluation after non-polimeric and polimeric paclitaxel stent implantation.In particular the investigators will use Taxus )as a polimeric stent)and Axxion (as a non-polimeirc)stent system.
- Trial name
- LISAII (NCT01375855)
- Testing
- Percutaneous transluminal Coronary Angioplasty
- Where
- Spain
- Volunteers
- 320 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Buerger Disease, Raynaud Syndrome
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease.
- Trial name
- BETOX (NCT05698979)
- Testing
- BOTOX INJECTION
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Toulouse
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Coronary Disease, Coronary Artery Disease
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ZoMaxx™ I (NCT00148356)
- Testing
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
- Where
- 29 sites in Australia, Belgium and 8 more
- Volunteers
- 401 people
- Sponsor
- Abbott Medical Devices